We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
REDEMPLO Arrowhead Australia Pty Ltd
Product name
REDEMPLO
Sponsor
Accepted date
Sep-2025
Active ingredients
plozasiran sodium
Proposed indication
REDEMPLO (plozasiran) is proposed to lower high levels of triglycerides in adults who have familial chylomicronaemia syndrome (FCS). It is intended for people whose FCS has been confirmed by genetic testing or a doctor’s diagnosis, and who have not had enough success with other standard treatments for lowering triglycerides.
Application type
A (new medicine)
Publication date
Sep-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.